Anixa Biosciences is trading 6.91% higher after hours at $2.96; the trial update may be a catalyst, though no source directly linked it to the move. - Shares fell 5.46% to $2.77 in the October 1 regular session. - The company said a second patient was treated in the fifth, highest-dose cohort of its Phase 1 ovarian cancer CAR-T trial. No dose-limiting toxicities had been observed through the first patient in that cohort.